DRUG-SENSITIVITY DISTRIBUTION OF PHLEGMY PATOGENIC BACTERIA FROM ACUTE EXACERBATION OF COPD INPATIENTS

SESSION TITLE: Chest Infections Posters SESSION TYPE: Original Investigation Posters PRESENTED ON: October 18-21, 2020 PURPOSE: To explore drug sensitivity and drug resistance of pathogenic bacteria in sputum from lower respiratory tract of acute exacerbation of COPD (AECOPD) inpatients thus providing evidence for selection of antibiotics during clinical practice. METHODS: From October 2018 to September 2019, clinical data (age, gender, sputum cultivation, drug sensitivity test) collected from 1250 cases of AECOPD inpatients admitted at respiratory & ICU departments of the second hospital affiliated to Jilin University were retrospectively analyzed to explore type classification, distribution range and drug resistance of pathogenic bacteria. RESULTS: 1.Among 1250 cases of AECOPD patients, sputum samples from 1186 cases (94.88%) were submitted for cultivation with positive rate of 51.34% (609/1186, Male: 298 cases, Female: 311 cases, Mean Age: 79.62).Among 609 sputum samples, 773 strains of pathogenic bacteria were cultivated, with 479 strains (61.70%) of gram-negative bacilli.Meanwhile, 55 strains (7.11%) of gram-positive bacilli.The rest were entirely fungus strains (316 strains/40.88%), mainly confirmed as Albicans saccharomyces.2.Drug sensitivity distribution of gram-negative bacilli were classified as following: highly resistant to 2nd generation cephalosporin, 3rd generation cephalosporin, quinolone and semi-synthetic penicillins without β-lactamase inhibitor; moderate resistant to 4th generation cephalosporin, aminoglycoside, cefoperazone-sulbactam and piperacillin-tazobactam; sensitive to carbapemems. CONCLUSIONS: Though Gram-negative bacilli infected by AECOPD cases are highly resistant to 2nd generation cephalosporin, 3rd generation cephalosporin and quinolone, 4th generation cephalosporin, compound agents of penicillin and β-lactamase inhibitor and carbapemems should be selected with preference for treatment according to empirical antibiotic therapy. CLINICAL IMPLICATIONS: Dynamic monitoring for changes concerning distribution and drug-resistance of pathogens is conducive to directing anti-infection treatment during clinical practice. DISCLOSURES: No relevant relationships by Yanbing Hu, source=Web Response No relevant relationships by Tiangang Ma, source=Web Response No relevant relationships by Qinghua Zhang, source=Web Response